The survival rate among those with lung cancer has improved by more than a quarter in the last five years, according to a new report. Four years ago, the United States Preventive Services Task Force ...

Lung (pulmonary) sarcoma is a rare type of cancer that forms in the blood vessels and supportive tissue in your lungs. Most lung cancers, including small cell and non small cell lung cancers, are ...

A cohort of 253 isolated LR resections from 3211 primary STS resections enabled evaluation of post-recurrence prognosticators with median 5.3-year follow-up and 83 disease-specific deaths. Higher LR ...

Cancer statistics have reached new heights — in good and not-so-good ways. The American Cancer Society (ACS) released its annual report on cancer trends this week, showing for the first time that more ...

Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...

Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...

– Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma "Our growing body of preliminary data demonstrated by Annamycin in the treatment of ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...

People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...